



DFIN CASE STUDY

# How Venue's High Security and Collaborative Design Delivered for Biopharma

Venue®  
by **DFIN**

 **LEADING**  
BIOSCIENCES



## CHALLENGE

# Keeping a clinical team on-task in a crisis


When COVID-19 began shutting down most U.S. workplaces, California-based Leading BioSciences, Inc. (LBS) was in the midst of a vital Phase 2 clinical trial to test the efficacy of its main drug. A shutdown would have meant a delay or even an end to their study.

To keep the study alive, LBS put DFIN's Venue to a novel use — sharing and managing clinical trial data — that revolutionized the way they do business.





## Top Documents



## Question & Answer

**Q Terms and Conditions**  
In our opinion, the unaudited interim condensed consolidated financial statements contain all adjustments (consisting ...

**A Investment**  
The Investor agrees to enter into this contract under the terms and conditions presented below. Amendment, addition, or

**Q Strategy**  
The Company will make payments to the Investor according to an agreed upon payment schedule. This schedule is not subject to

**A Deposits and Withdrawals**  
The investment objectives of the Company are to maximize current income to the extent that such ventures preserve the

## SOLUTION

# The virtual data room built for biopharma


Venue's encrypted virtual data room met all of the stringent security requirements regarding patients' protected health information. Because the software was so intuitive and easy to use, workers at the study's 11 trial sites and independent study monitors quickly got up to speed. LBS plans to use Venue for future studies thanks to its integrated redaction capability as well as cost and time savings.



Our consolidated financial position as of [redacted] the interim results of operations for the three months ended [redacted] and September 30, 2020, and cash flows for 2020. Operating results for the three months ended March 31, 2020 and [redacted] are not necessarily indicative of the results that may be expected for a full year or any future [redacted] schedule is not subject to amend unless both parties agree. [redacted]



## Creating Room



### INSTANT SET UP

Venue's highly intuitive user interface took minutes for study personnel to submit medical record data remotely.



### TRUSTED SECURITY

Meeting HIPAA and other privacy concerns was no problem thanks to Venue's 256-bit encryption.



### EASY COLLABORATION

All teams were able to submit and access documents quickly and easily.

“

Working with DFIN's Venue left us questioning why we were doing things how we have always done them. Using the platform has certainly opened the eyes of our company and the industry in general. We found a new way to do business that offers efficiency and cost savings and is a long-term solution.”

**INGE BEAR**

Chief Development Officer, Leading BioSciences





Venue®

# Maintaining security, enhancing efficiency



**SECURE**

Protects your most sensitive information with 256-bit encryption, anti-virus protection and the highest levels of infrastructure security.



**EFFICIENT**

Easy-to-use from day one, Venue streamlines operations while leveraging AI-powered tools that save you time.



**INTUITIVE**

Whatever industry you're in, Venue lets you customize and manage your data room without any additional plug-ins or downloads.



**EXPERT-DRIVEN**

With a dedicated regional project manager and 24/7/365 client services, you get the support of DFIN experts who are committed to your success.

PERMISSIONS BASED BY USER GROUP

COMPANY NAME

EST. DATE

LOREM IPSUM

Lorem ipsum

elit ullamcorper dignissim cras tincidunt. Tincidunt nunc pulvinar sapien et ligula ullamcorper

tristique sollicitudin nibh sit amet commodo. Pretium fusce id velit ut. Integer

Nulla facilisi

neque ornare aenean euismod. Imperdiet proin fermentum leo vel orci. Id interdum

egestas fringilla.

GOVERNMENT  
GRADE  
ENCRYPTION

AUTO REDACTION



# Get in touch.

**DFIN**Solutions.com

35 West Wacker Drive  
Chicago, Illinois 60601  
United States  
+1 866 319 7064

APAC: +852 2522 3803  
EMEA: +44 203 047 6100  
LATAM: +55 11 3031 6327